Issue No. 51, May 2026Electronic ISSN 2521-3881 |
||
| Issue No. 51 - May2026 | ||
| 7-13 | Review Article | Diagnosis and Early Detection of Lung Cancer: Present and Future Approaches | |
|
Tarig Fadelelmoula1 1 Department of Internal Medicine, College of Medicine and Health Sciences, National University of Science and Technology, Sohar, Sultanate of Oman |
||
| Abstract | ||
|
Lung cancer is the leading cause of cancer deaths worldwide, with most cases found late. This review summarizes evidence on lung cancer diagnostics, highlights findings from important screening trials, and discusses new technologies shaping future approaches. It describes recent advances like artificial intelligence, radiomics, and molecular biomarkers for early detection. The review compares diagnostic tools, addresses barriers to their use, and presents new results from recent trials and technologies. By highlighting innovations and contrasting them with current practices, it clarifies the evolving landscape and offers strategies to improve early diagnosis. The review used a comprehensive PubMed search with the terms: "lung cancer AND (screening OR early detection OR diagnosis OR biomarkers OR artificial intelligence OR radiomics)." It included articles from 2010 to April 2024. Only English articles focused on adult human studies were included. The review analyzed original research, systematic reviews, meta-analyses, and major screening trials. Twenty-eight articles met these criteria, including five major screening trials. Five themes are identified: Enhanced Endoscopic Diagnostics, Liquid Biopsy and Molecular Biomarkers, Artificial Intelligence and Radiomics, Novel Biomarkers, and Integrated Screening Approaches. Low-dose computed tomography (LDCT) trials such as National Lung Screening Trial (NLST), Dutch Belgian lung cancer screening trial (NELSON), UK Lung Cancer Screening Trial (UKLS), and Multicentric Italian Lung Detection (MILD) show mortality benefit, but barriers remain. New diagnostic approaches, including liquid biopsy, AI with radiomics, and volatile organic compound profiling, may help overcome these barriers and support current strategies.
Keywords: lung cancer, early detection, screening, low-dose CT, liquid biopsy, artificial intelligence, radiomics, biomarkers. |
full article | |
| 2 | 14-21 |
Original Article | Immunohistochemical Expression of BCL2 (B cell lymphoma 2) in Invasive Breast Carcinoma and its Correlation with Clinicopathological Parameters |
|
Prajakta A Shinde, Siddhi Gaurish Sinai Khandeparkar, Bageshri P. Gogate, Mohini Shahaji Patil, Sanika Patrikar, Mitali Anil Khot, Shrutika Ashok Bodhale, Pratiksha Krishna Sarak Smt. Kashibai Navale Medical College and General Hospital |
||
| Abstract | ||
|
Introduction: Breast cancer (BC) is the most common cancer and foremost cause of death in women.
Aim: This study was conducted to study the BCL2 expression in BC and its correlation with other clinicopathological parameters such as histological grade, tumor size, lymph node status, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), Ki67 status and molecular subtypes in Indian setting.
Materials and methods: Fifty cases of BC diagnosed between 2015 and 2020 were included in the study. A technique of manual tissue microarray was employed for the analysis of expression of IHC markers such as BCL2, ER, PR, Her2/neu, Ki67, CK5/6 and EGFR in all cases. Results were subjected to statistical analysis.
Results: BCL2 positivity was seen in 36% cases of BC of which 22.22% were HER2 enriched, 33.33% were hormone receptor positive, 38.89% were triple negative (TNBC) non-classifiable, and 5.56% were of basal like BC (BLBC) molecular subtype. Maximum cases of BC showing loss of BCL2 expression showed a statistically insignificant association with higher tumor grade and stage, lymph node positivity, presence of lymphovascular invasion, absence of ER/PR and HER2/neu expression, and Ki67 positivity. 34% cases were of hormone receptor positive BC cases. BCL2 was found positive in 35.29% of hormone receptor positive BC cases. 44% cases were TNBC. BCL2 was found positive in 36.36% of TNBC cases. 20% cases were BLBC. BCL2 was found positive in 10% of BLBC cases. Maximum cases of hormone receptor positive BC, TNBC and BLBC showing loss of BCL2 expression showed a statistically insignificant association with higher grade and stage, lymph node positivity, lymphovascular invasion, and Ki67 expression.
Conclusion: BCL2 can serve as a useful prognostic marker and merits inclusion in the routine IHC panel for breast cancer, as it may contribute to the development of individualized, tailored therapeutic strategies.
Keywords: BCL2, breast carcinoma, prognosis, hormone receptor positive, TNBC, BLBC.
|
full article | |
| 3 | 22-25 | Editorial | Artificial Intelligence-Augmented Breast Ultrasound: Advancing Diagnostic Precision and Equity in Cancer Care in Kuwait |
|
Michael A Masoomi, PhD, MRCP(Lon)1,2, Latifa Al-Kandari, MD1 1 Department of Radiology, ADAN Hospital, KUWAIT 2 Department of Research and Innovation, Portsmouth University Hospital, UK *Corresponding author: masoomim@sky.com |
||
| Abstract | ||
|
Breast cancer poses a significant public health concern in Kuwait, accounting for 37.4% of all newly diagnosed female cancer cases as reported by the Kuwait National Cancer Registry. The rising incidence, coupled with variability in imaging expertise, contributes to diagnostic delays and disparities in patient care. Artificial intelligence (AI) has rapidly become a transformative tool supporting breast ultrasound, enhancing diagnostic accuracy, standardization, and assistance for non-specialist providers. This editorial evaluates the potential of AI-enabled ultrasound to improve diagnostic performance by increasing sensitivity, decreasing false positive rates, and reducing inter-observer variability, while also addressing structural inequities that affect cancer outcomes within the region. Recent advancements in deep learning and radiomics-based tools are reviewed, alongside considerations related to governance and ethics, and recommendations for practical integration of AI solutions into national breast cancer management pathways are provided. The adoption of AI-augmented ultrasound holds considerable promise for strengthening Kuwait's capacity for early detection and advancing equitable, high-quality cancer care.
Keywords: Artificial intelligence, breast ultrasound, diagnostic precision, cancer care, Kuwait, equity.
|
||
| full article | ||
| 4 | 26-35 |
Original Article | Epstein-Barr Virus Seroprevalence and Associated Risk Factors in Head and Neck Squamous Cell Carcinoma: A Cross-Sectional Study from Aden, Yemen |
|
Gamal Abdul Hamid1,2, Abdullateef Mohammed Atef1,2 1 National Oncology Center Aden 2 Faculty of Medicine and Health Sciences University of Aden |
||
| Abstract | ||
|
Background: Head and neck squamous cell carcinoma (HNSCC) incidence in Yemen shows distinct patterns, influenced by unique risk factors like qat chewing alongside tobacco, smoking, and viral infections. Epstein-Barr virus (EBV) is an established oncogenic virus, particularly for nasopharyngeal carcinoma (NPC). This study investigated EBV seroprevalence, infection status, and associations with demographic and risk factors in Yemeni HNSCC patients. Methods: A cross-sectional study was conducted at the National Oncology Center, Aden, Yemen (Jan-Dec 2023). One hundred histologically confirmed HNSCC patients provided informed consent. Data on demographics, tumor characteristics (site, stage, histology), risk factors (tobacco, smoking, qat chewing, family history), and blood group were collected via records and questionnaires. EBV infection status (primary, past, reactivation) was determined using Chemiluminescent Immunoassay (CLIA) for EA IgG, NA IgG, VCA IgG, and VCA IgM. Results: Patients had a mean age of 53.2 ± 14.7 years, with peaks in 36-54 (41%) and 55-73 (40%) years. Males predominated (M:F = 2.45:1). The nasopharynx was the most common site (48%). Most patients presented with advanced disease (Stage III: 57%, Stage IV: 29%). Qat chewing was the leading risk factor (74%), followed by tobacco use (68%) and cigarette smoking (50%), showing significant associations (p<0.05). EBV infection was highly prevalent: 8% primary, 39% past, 53% reactivation (p<0.001). CLIA positivity was high for VCA IgG (99%), NA IgG (88%), and EA IgG (61%). EA IgG positivity was significantly associated with infection status (p<0.001). Reactivation infection was strongly linked to NPC (66%). Blood group A was associated with increased NPC risk (52.0% of NPC patients). Conclusion: This study highlights a high burden of EBV infection, particularly reactivation, among Yemeni HNSCC patients, with a striking predominance of NPC. Qat chewing emerges as a major local risk factor alongside tobacco and smoking. The association of EBV reactivation and blood group A with NPC underscores the virus's significant role in HNSCC pathogenesis within this population. These findings emphasize the need for EBV screening in HNSCC management and targeted public health interventions against modifiable risks like qat and tobacco in Yemen. Keywords: Epstein-Barr Virus, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Pathogenesis, Risk Factors, Qat Chewing, Tobacco, Blood Group, Yemen. |
||
| full article | ||
| 5 | SP |
Special Issue Featuring Original Articles and Conference Proceedings Regional Oncology Conference 13th GFFCC Annual Conference: Cancer: Reality and Challenges State of Kuwait, 02-03 February 2026 |
|
This special issue includes original manuscripts followed by conference proceedings.
The proceedings contain poster abstracts, speaker's presentation abstracts, and conference recommendations.
Conference Proceedings PDF: Click here to view/open the proceedings |
||